This interview discusses Little Green Pharma’s (ASX:LGP) record-breaking quarterly results for June 2024, highlighting a 12% increase in revenue and significant cash receipts. CEO Paul Long elaborates on the company’s growth drivers, including new product sales in Australia and Europe, and outlines their strategy to maintain market share and expand in emerging European markets.
More From The Market Online
Australian Gold and Copper: Maiden resource complete, growth story continues
HotCopper talks to AGC MD Glen Diemar as precious and critical metals explorer Australian Gold and…
- Isaac McIntyre
- 1 min
- 17 February 2026 09:05 (AEDT)
HotCopper Highlights, Week 8: Zip unfastened; Coles in trouble, BHP’s India pivot & more
Good Afternoon and welcome to the latest edition of HotCopper Highlights where we go through the stocks and announcements you were watching this week on
- Jonathon Davidson
- 3 mins
- 20 February 2026 15:46 (AEDT)
Temas Resources hunting for REEs in historic core
Temas Resources is examining 181 historic holes for iron, titanium, vanadium, chromium, gallium, scandium and other…
- Colin Sandell-Hay
- 2 mins
- 20 February 2026 15:22 (AEDT)
Eclipse Metals obtains promising Grønnedal metallurgical results
Eclipse Metals has reported encouraging preliminary Phase 1 metallurgical results from the Grønnedal rare earth element…
- Colin Sandell-Hay
- 2 mins
- 20 February 2026 14:21 (AEDT)
